Drugs & Therapy Perspectives

, Volume 14, Issue 4, pp 13–16 | Cite as

Vinorelbine-based regimens for NSCLC make pharmacoeconomic sense

Drug Economics and Quality of Life


Vinorelbine Road Traffic Accident Good Supportive Care Vindesine Median Survival Duration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Cancer Society. Lung cancer 1998 facts & figures [online]. American Cancer Society; 1999. Available from: [Accessed 1999 Feb 22]Google Scholar
  2. 2.
    Kelly P, Clancy L. Is the use of chemotherapy justified in non-small cell lung cancer? Drugs Aging 1994 Jan; 4: 1–8PubMedCrossRefGoogle Scholar
  3. 3.
    American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997 Aug; 15: 2996–3018Google Scholar
  4. 4.
    Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998 Dec; 16(12): 3900–12PubMedGoogle Scholar
  5. 5.
    Shoheiber O, Schrogie JJ, Johnson N. Non-small cell lung cancer: a cost of illness study [abstract]. Pharmacotherapy 1996 Jan–Feb; 16: 136Google Scholar
  6. 6.
    Coukell AJ, Noble S, Faulds D. Vinorelbine in advanced non-small cell lung cancer. Pharmacoeconomics 1999 Apr; 15(4): 405–17PubMedCrossRefGoogle Scholar
  7. 7.
    Le Chevalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced nonsmall-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994 Feb; 12: 360–7PubMedGoogle Scholar
  8. 8.
    Evans WK. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC. Oncology 1998 Mar; 12(3) Suppl. 4: 18–26PubMedGoogle Scholar
  9. 9.
    Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995 Sep; 13: 2166–73PubMedGoogle Scholar
  10. 10.
    Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 1992; 146: 473–81Google Scholar
  11. 11.
    Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993 Sep 15; 85(18): 1460–74PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations